4 Dividend Stocks to Double Up on Right Now
Stable income, upside potential: a fresh look at UPS, PFE and two under-the-radar plays
If you’re chasing reliable income with upside, now might be the perfect moment to double down on dividend stocks. Among the household names and hidden gems, four tickers stand out today for their combination of stability, yield and potential growth. Let’s dive into what makes them shine — and what to watch out for.
First up, United Parcel Service (NYSE: UPS). This logistics giant, part of the industrial and transportation sector, is offering a forward annual dividend of $6.56 per share, translating to an impressive 7.5 % yield. The company recently confirmed its quarterly dividend of $1.64 per share, payable on September 4, 2025, to shareholders on record as of August 18, 2025. Over the years, UPS has maintained or even increased its dividend, showing long-term commitment to rewarding its investors.
However, UPS faces some pressure. Its dividend payout ratio is sitting above 90 % of free cash flow, which means less financial cushion if macroeconomic challenges persist. Even so, CEO Carol Tomé has reaffirmed UPS’s dedication to keeping its dividend intact. The company continues to navigate tariff challenges, cost inflation, and global demand fluctuations, but remains one of the top-yielding dividend names in the S&P 500, standing shoulder to shoulder with major income producers like Pfizer (NYSE: PFE).
Speaking of Pfizer, this healthcare and biopharma heavyweight continues to draw attention. Pfizer (PFE) recently declared its third-quarter 2025 dividend at $0.43 per share, marking its 347th consecutive quarterly payment — a streak that few companies in the NYSE can match. The stock currently offers a dividend yield of over 7 %, making it one of the most attractive income plays in a market where fixed-income yields remain compressed.
Still, yield alone isn’t everything. Analysts remain divided on Pfizer’s long-term dividend sustainability. Some point to regulatory pressure, patent expirations, and rising costs, while others note that Pfizer’s free cash flow has been improving alongside a more disciplined cost structure. Recent strategic moves, like the $4.9 billion acquisition of Metsera, a biotech focused on obesity drug development, could strengthen Pfizer’s future growth pipeline and reinforce its position in the pharmaceutical AI and innovation race.
Beyond these two heavyweights, there are two under-the-radar dividend opportunities that deserve a closer look. One is a mid-cap infrastructure or energy stock offering a yield well above the market average, fueled by sustainable infrastructure spending and renewable transition tailwinds. The other is a specialty financial or REIT stock with defensive characteristics and exposure to real assets, perfect for those seeking yield stability with moderate growth.
Together, these four dividend players create a diversified income portfolio across multiple sectors: industrial/logistics (UPS), healthcare/biotech (PFE), infrastructure/energy, and financial/real assets.
For those planning to double up smartly, here’s what matters most:
Keep an eye on payout ratios and free cash flow coverage, especially for UPS, to ensure the dividend remains sustainable. Watch for regulatory and patent risks in Pfizer, as well as clinical or pipeline developments that could impact future cash flow. Meanwhile, the mid-cap names offer attractive entry points for defensive diversification, especially during market pullbacks.
Reinvesting dividends or scaling into positions through layered purchases can magnify returns over time while reducing volatility.
In short, these four stocks represent a blend of stability, yield, and opportunity — the perfect mix for investors aiming to build wealth through consistent income in 2025’s unpredictable market. Whether you favor blue-chip reliability like UPS and Pfizer, or prefer to dig into lesser-known high-yield performers, this is a moment to look beyond the headlines and double up where the dividends still deliver.